Table 2. 50 mg/d 4 weeks on, 2 weeks off vs. 37.5 mg continuous daily dose regimen of sunitinib in NSCLC.

		Sunitinib 50 mg/d 4/2 (n =63)	37.5 mg/d CDD (n =47)
Efficacy	ORR (%)	11.1	2.1
	PFS (week)	12.0	12.3
	OS (week)	23.4	37.1
Adverse events (%, grade 1-2/3-4)	Fatigue	41/29	43/17
	Pain	43/17	47/2
	Nause/Vomiting	43/10	38/2
	Stomatitis	40/3	29/2
	Hypertension	6/5	19/9
	Hemoptysis	NR	15/2
	Neutropenia	44/5	NR/9
	Thrombocytopenia	49/5	NR/0

CDD: continous daily dose; PFS: progression-free survival; OS: overall survival; ORR: objective response rate; NR: not reported.